PRESS RELEASE published on 01/04/2024 at 12:00, 2 years 8 months ago Tryp Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial for the Treatment of Fibromyalgia at The University of Michigan Tryp Therapeutics Inc. is pleased to announce the dosing of the first patient in a Phase 2a clinical trial for fibromyalgia using their proprietary IV-infused psilocin, TRP-8802. With positive results, the company aims to further develop TRP-8803 to provide relief to millions of patients suffering from chronic pain. Learn more about Tryp's innovative therapies at www.tryptherapeutics.com. Tryp Therapeutics Inc TRP-8802 Fibromyalgia IV-infused Psilocin Chronic Pain Relief
REGULATED PRESS RELEASE published on 01/04/2024 at 11:55, 2 years 8 months ago Edenred - Disclosure of Share Capital and Voting Rights as of December 31, 2023 This press release discloses the share capital and voting rights of Edenred as of December 31, 2023, in accordance with the French Commercial Code and the General Regulations of the Autorité des marchés financiers. The total shares outstanding, potential voting rights, and exercisable voting rights are provided, excluding rights attached to shares held in treasury. More information can be found on edenred.com, Investors/Shareholders section then Regulated Information. Edenred Share Capital Voting Rights French Commercial Code Investors
REGULATED PRESS RELEASE published on 01/04/2024 at 11:55, 2 years 8 months ago Edenred - Déclaration du nombre d'actions et de droits de vote au 31 décembre 2023 Edenred déclare le nombre d'actions et de droits de vote conformément à la réglementation en vigueur. Toute l’information est disponible sur le site web edenred.com, rubrique Investisseurs / Actionnaires Edenred Déclaration Nombre D'actions Droits De Vote Information Réglementée
REGULATED PRESS RELEASE published on 01/04/2024 at 10:40, 2 years 8 months ago LNA Santé : Répartition de capital et des droits de vote attachés aux actions au 31/12/2023 Déclaration de répartition de capital et droits de vote pour LNA Santé au 31/12/2023 par Société Générale conformément à l'article 223-16 du règlement général de l'Autorité des Marchés Financiers Société Générale Article 223-16 LNA Santé Droits De Vote Répartition De Capital
REGULATED PRESS RELEASE published on 01/04/2024 at 08:11, 2 years 8 months ago Bilan Semestriel du Contrat de Liquidité d'Engie au 31 décembre 2023 Bilan semestriel du contrat de liquidité de la société ENGIE avec Rothschild Martin Maurel. Détail des transactions et réduction du montant en espèces ENGIE Rothschild Martin Maurel Bilan Semestriel Liquidité Réduction Montant Espèces
PRESS RELEASE published on 01/04/2024 at 08:00, 2 years 8 months ago Canadian Overseas Petroleum Ltd Announces Conversion of Bond Payments Canadian Overseas Petroleum Limited announces the issuance of 305,598,679 common shares for the settlement of Conversion Payment amounts. The Company now has a total of 1,344,370,498 common shares issued and outstanding. Shareholders may use this figure for the necessary calculations under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules. The Common Shares will be admitted to the FCA's Official List and to trading on the London Stock Exchange's main market for listed securities within the next twelve months. For further information, please refer to the contact details provided in the press release. Canadian Overseas Petroleum Limited Common Shares Issuance Conversion Payment Settlement London Stock Exchange Oil And Gas Exploration
PRESS RELEASE published on 01/04/2024 at 07:00, 2 years 8 months ago Biophytis annonce la publication des résultats de son étude de phase 2-3 COVA dans eClinicalMedicine, partie de The Lancet Biophytis annonce la publication des résultats de son étude de phase 2-3 COVA dans eClinicalMedicine, partie de The Lancet. Biophytis, société de biotechnologie, annonce des résultats prometteurs pour le traitement des symptômes respiratoires des formes sévères de COVID-19 Biophytis COVID-19 EClinicalMedicine Étude De Phase 2-3 COVA Société De Biotechnologie
PRESS RELEASE published on 01/04/2024 at 07:00, 2 years 8 months ago Biophytis announces the publication of the results of its COVA phase 2-3 study in eClinicalMedicine, part of The Lancet Biophytis announces the publication of the results of its COVA phase 2-3 study in eClinicalMedicine, part of The Lancet. The publication highlights the positive results of Sarconeos (BIO101) in reducing the risk of death or respiratory failure in adults hospitalized with severe respiratory symptoms due to COVID-19. Biophytis will also host press conferences to discuss the potential and clinical benefits of Sarconeos (BIO101) in severe forms of COVID-19 and its exploration in the treatment of other respiratory viral infections. For more information, visit www.biophytis.com Biophytis COVA Phase 2-3 Study Sarconeos (BIO101) Publication Severe COVID-19 Treatment Respiratory Viral Infections Clinical Benefits Of Sarconeos (BIO101)
PRESS RELEASE published on 01/04/2024 at 02:00, 2 years 8 months ago Runway Influence: Harnessing The Power of Model Influencers for Unparalleled Brand Success Runway Influence, a leading influencer marketing agency in Los Angeles, specializes in collaborating with high-profile models, celebrities, and renowned brands. Their unique niche in working exclusively with a network of model influencers offers a sophisticated and credible approach to brand endorsements. The agency's visionary leadership, commitment to innovation, and diverse clientele enable them to create impactful influencer campaigns for global brands. Their recognition in prestigious publications underscores their expertise and prominence in the dynamic world of digital marketing and influencer engagement. Runway Influence Influencer Marketing Model Influencers Digital Marketing Brand Collaboration
PRESS RELEASE published on 01/04/2024 at 00:20, 2 years 8 months ago Redishred Capital Corp. Announces the Acquisition of MDK Recycling LLC Redishred Capital Corp announces the successful completion of its acquisition of MDK Recycling LLC, a Michigan-based company offering paper and hard drive shredding, product destruction, paper recycling, and scanning services. The acquisition is expected to significantly contribute to Redishred's cash flows and earnings, allowing the company to expand its shredding and scanning footprint in the United States and enter the Detroit, Michigan market. The purchase price for this acquisition, including earnouts, is estimated to be between $0.5 million and $0.8 million USD, depending on the performance of MDK relative to earn-out targets. For more information about this acquisition, please visit the Redishred website or contact the company's CEO or CFO. Acquisition Redishred Capital Corp MDK Recycling LLC Shredding Services Paper Recycling
Published on 09/26/2026 at 01:00, 14 hours 26 minutes ago Guanajuato Silver Renews Base Shelf Prospectus
Published on 09/26/2026 at 01:00, 14 hours 26 minutes ago Findev Inc. Provides Update on Victoria Park Loan Exposure and Expected Accounting Impairment
Published on 09/25/2026 at 22:15, 17 hours 11 minutes ago Rocky Shore Gold Closes First Tranche of Non-Brokered Private Placement
Published on 09/25/2026 at 17:30, 21 hours 56 minutes ago Goldcliff Announces Unit and Flow Through "LIFE" Offerings
Published on 09/25/2026 at 15:00, 1 day ago HM Exploration Provides Program Update for the Lewis Pilley's Project
Published on 09/26/2026 at 15:15, 11 minutes ago Timur Turlov Elected FIDE President, Becomes First Kazakh to Lead World Chess
Published on 09/26/2026 at 07:45, 7 hours 41 minutes ago Green SM Begins Pilot Operations In The Netherlands, Further Expanding Its Presence In Europe
Published on 09/26/2026 at 00:01, 15 hours 25 minutes ago Photon Energy N.V. Sells 7.6 MWp of PV Operational Assets in Slovakia
Published on 09/25/2026 at 18:30, 20 hours 56 minutes ago 029 Group SE: Publication of Half-Year Report 2026
Published on 09/25/2026 at 17:45, 21 hours 41 minutes ago COGRA : ASSEMBLÉE GÉNÉRALE MIXTE DU 16 OCTOBRE 2026 / MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025/2026
Published on 09/25/2026 at 17:40, 21 hours 46 minutes ago Availability of the 2026 half-year financial report